ONEMEDNET CORP
ONMDNASDAQTrading Snapshot
- Day Range
- $5.14 – $5.28
- 52-Week Range
- $0.49 – $4.22
- Volume
- $2.44B
- Avg Volume
- $2.29B
- Shares Outstanding
- 57.0M
- Next Earnings
- Dec 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $292,000
- P/E Ratio
- -3.8
- P/S Ratio
- 24.8x
- EPS (TTM)
- $-0.15
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.0%
Why Investors Own ONMD
- ✓High-growth profile — revenue up +58.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ONEMEDNET CORP
ONMD
StockOtter · stockotter.spaceAbout ONEMEDNET CORP
OneMedNet Corporation offers advanced solutions for clinical imaging. Their core product, iRWD, is an artificial intelligence-driven platform that securely anonymizes, searches for, and organizes imaging data. This system is utilized by their extensive network of medical and academic research institutions, with the goal of fostering significant progress in medical research, new discoveries, and diagnostic techniques across the broader field of life sciences. The company's operations are based out of Eden Prairie, Minnesota.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
OneMedNet Corporation Announces 1-for-10 Reverse Stock Split
MINNEAPOLIS, Sept. 25, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “Company,” “we,” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World
Atropos Health Scales Federated Evidence Network with Multimodal Data Partners to Accelerate Health Analytics and AI Model Development
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in real-world evidence (RWE) generation from high-quality healthcare data, today announced a significant expansion of its federated Atropos Evidence™ Network.
OneMedNet Expands Commercial Reach Through Multi-Year Resale Agreement with Atropos Health
MINNEAPOLIS, Sept. 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us,” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), t
OneMedNet Reports Record Bookings as Faster Fulfillment Begins
MINNEAPOLIS, Sept. 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI
OneMedNet (NASDAQ:ONMD) and Certara (NASDAQ:CERT) Financial Comparison
Certara (NASDAQ: CERT - Get Free Report) and OneMedNet (NASDAQ: ONMD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strengt
OneMedNet's iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company
MINNEAPOLIS, Aug. 31, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-